A Twelve Week Study of Prototypes Mouth Rinses

Completed · Phase 4

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the safety and efficacy of two essential oil containing experimental mouth rinse formulations and an essential oil containing mouth rinse compared to a hydroalcohol control mouth rinse for the reduction of gingivitis and plaque when used as an adjunct to tooth brushing during a twelve-week product usage period.

Key facts

Study ID: NCT05526586
Run by: Johnson & Johnson Consumer Inc. (J&JCI)
People needed: 192
Starts: 2022-08-31
Expected to finish: 2022-12-08
Last updated by the study team: 2023-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Able to comprehend and follow the requirements and restrictions of the study (including willingness to use the assigned study products per instructions, availability on scheduled visit dates and likeliness of completing the clinical study) based upon research site personnel's assessment
Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial
Able to read and understand the local language (participant is capable of reading the documents)
Adequate oral hygiene (that is, brush teeth daily and exhibit no signs of oral neglect)
Adults, 18 years of age and older, in good general and oral health without any known allergy to commercial dental products or cosmetics
Evidence of being fully vaccinated for coronavirus disease 2019 (COVID-19) (adults 60 years and older)
Negative pregnancy urine tests (females of child-bearing potential only)
Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the study
A minimum of 20 natural teeth with scorable facial and lingual surfaces. Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, or third molars will not be included in the tooth count
A mean gingival index greater than or equal to (>=) 1.95 per the Modified Gingival Index at Baseline
A mean plaque index >=1.95 per the 6 site Turesky modification of the Quigley-Hein Plaque Index
Greater than or equal to 10 percent (%) bleeding sites at Baseline
Absence of significant oral soft tissue pathology, excluding plaque-induced gingivitis, based on a visual examination and at the discretion of the Investigator
Absence of advanced periodontitis based on a clinical examination and discretion of the dental examiner with probing depths of 4 millimeters (mm) or less except for two sites allowed with a probing depth of 5mm at Baseline
Absence of fixed or removable orthodontic appliance or removable partial dentures

You may not qualify if…

History of significant adverse effects, including sensitivities or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses and red food dye
Dental prophylaxis within four weeks prior to Baseline visit
More than two sites that have periodontal pockets depths measuring 5mm or greater in depth
History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures
Use of antibiotics, anti-inflammatory or anticoagulant therapy, phenytoin sodium or diphenylhydantoin, cyclosporin A, immunostimulants/ immunomodulators during the study or within the one month prior to the Baseline exam. Intermittent use of certain anti-inflammatory medication (ibuprofen, Aspirin); oral steroids and calcium channel blockers are acceptable at the discretion of the investigator
Use of chemotherapeutic anti-plaque/anti-gingivitis products such as triclosan, essential oils, cetylpyridinium chloride, sodium fluoride with CPC, stannous fluoride, zinc or chlorhexidine digluconate containing mouth rinses and toothpastes within the four weeks prior to the Baseline exam
Known allergy or sensitivity or history of significant adverse effects to any of the investigational product and/or product ingredients (or other ingredients in the products)
Consumption of probiotic drinks/supplements within one week prior to Screening/Baseline
Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing which can affect interpretation of study results)
Self-reported smokeless tobacco user including snuff, chewing tobacco, vaping and e-cigarette usage
Males with a pregnant partner or a partner who is currently trying to become pregnant
Suspected alcohol or substance abuse (example, amphetamines, benzodiazepines, cocaine, marijuana, opiates)
Significant medical or oral condition which may interfere with a subject's participation in the study, including cancer, chronic kidney disease, COPD (chronic obstructive pulmonary disease), immunocompromised state (weakened immune system) from solid organ transplant, serious heart conditions, (such as heart failure, coronary artery disease, or cardiomyopathies) Sickle cell disease, Type 2 diabetes mellitus at the discretion of the Investigator
Participation in any clinical trial within 30 days of Screening visit
Diagnosed Temporo-mandibular joint dysfunction/disorder
Subjects who wear bruxing devices, dental aligners, retainers
Subjects who were previously screened and ineligible or were randomized to receive investigational product
Subjects who are related to those persons involved directly or indirectly with the conduct of this study (that is, principal investigator, sub-investigators, study coordinators, other site personnel, employees of Johnson \& Johnson subsidiaries, contractors of Johnson \& Johnson, and the families of each)
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
COVID-19 restrictions: Participants who fail to meet the criteria of the site's screening consent for Preventing Infection in the site's COVID-19 consent form

Where it is running

Salus Research, Inc. — Fort Wayne, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.